Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $15.00.
Several equities analysts recently commented on the stock. Citigroup increased their price objective on shares of Cogent Biosciences from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Robert W. Baird increased their price target on Cogent Biosciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research note on Thursday, September 5th. Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Cogent Biosciences in a research report on Wednesday, August 7th. Wedbush reaffirmed a “neutral” rating and issued a $11.00 target price (up previously from $10.00) on shares of Cogent Biosciences in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. cut their price target on Cogent Biosciences from $22.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th.
View Our Latest Stock Report on COGT
Hedge Funds Weigh In On Cogent Biosciences
Cogent Biosciences Stock Performance
Shares of COGT opened at $11.25 on Friday. Cogent Biosciences has a 52-week low of $3.67 and a 52-week high of $12.14. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -4.54 and a beta of 1.71. The business’s fifty day moving average is $10.30 and its 200-day moving average is $8.77.
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its earnings results on Tuesday, August 6th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same quarter in the previous year, the company posted ($0.59) earnings per share. As a group, research analysts forecast that Cogent Biosciences will post -2.25 EPS for the current fiscal year.
About Cogent Biosciences
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
See Also
- Five stocks we like better than Cogent Biosciences
- What is a Death Cross in Stocks?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Differences Between Momentum Investing and Long Term Investing
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.